L. Clementi
Boehringer Ingelheim (Italy)(IT)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Peptidase Inhibition and Analysis, HER2/EGFR in Cancer Research, Colorectal Cancer Treatments and Studies, Cancer therapeutics and mechanisms
Most-Cited Works
- → A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors(2015)42 cited
- → Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study(2020)31 cited
- → Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Non–Small-Cell Lung Cancer(2014)30 cited
- → Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies(2021)17 cited
- → A phase I dose-escalation study of volasertib (BI 6727) combined with nintedanib (BIBF 1120) in advanced solid tumors.(2013)7 cited
- → Afatinib in EGFR TKI-naïve patients (pts) with locally advanced/metastatic NSCLC harbouring EGFR mutations: An interim analysis of a phase IIIB trial(2019)3 cited
- → Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials(2019)2 cited
- → The burden of obesity in primary care in Italy: Italian real-world overweight/obesity study (ITROS)(2025)1 cited
- → Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC(2019)1 cited
- → 9007 ORAL Phase II Study of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker, in Patients With EGFR FISH-positive Advanced NSCLC(2011)1 cited